
Learnings from Launching a Venture Capital Fund in S.E. Asia at the Height of COVID-19
Venture Capital
Pre-COVID-19, I was involved in putting together a S.E. Asian Seed Fund with Singapore-based VC Vulpes Investment Management, and we were seeing some positive traction…
Author: May Myat Noe Oo
Date: February 17, 2021
Pre-COVID-19, I was involved in putting together a S.E. Asian Seed Fund with Singapore-based VC Vulpes Investment Management, and we were seeing some positive traction.
The fund raise marketing focused on the many positive attributes of the Region:
- Fastest growing economy in the world
- Massive mobile phone penetration/adoption and use
- Most resilient Region in global economic / health disasters and fastest in terms of recovery
- Massive population — especially under 30 years of age
- Increasing size and quality of tech / entrepreneurial talent pool
And then COVID-19 struck.
The world realised this was something different. This was going to be way bigger than MERS or SARS, and many countries began to shut borders. The financial world responded the way it does; it started to price in risk. This time the risk was big, very big, unprecedented big…
Business responded the way business does to this kind of uncertainty and threat. They started to reduce any variable costs they could first, then closed down any activities they thought would not be successful or feasible given the new market conditions and jettisoned any people or fixed costs that they could.
The listed equity markets experienced major adjustments; many early-stage investors experienced carnage within their portfolios particularly if they had exposure to tourism, travel, live events, or any industries supplying, dependent upon, or affiliated with these sectors. For most investors, making major commitments to a new VC Fund was not top of mind and would be deferred until more information on how deep this thing will go and for how long.
It became apparent that this virus was going to impact international travel for a long time. As most countries around the world closed their borders, introduced quarantine periods, and the first countries affected started to see second waves, it was obvious international travel was off the cards.
At this stage, I spoke at length with Field Pickering, the Head of Venture Capital at Vulpes Investment Management:
Should we proceed? Given the financial markets’ uncertainty, investor concern, restrictions on travel, and therefore our ability to get face to face with investors during the capital raising period and the founders during the investment period.
If we were to proceed, what would we need to change?
We appreciated there was short-term investor resistance, however, we believed there would be enough investors who would see this as an excellent time to invest if you invest in the right people/businesses and industry sectors.
Many excellent founders and businesses would require capital at a time when the majority of investors would be spooked like “deers in the headlights.” Founders who were still reliant on investor capital and not sufficiently cashed up would quickly need to raise capital. If we had capital, we could be there for those great founders/businesses, and potentially our investors would benefit from lower valuations.
We decided to go for it.
We reduced the fund size, shortened the investment period (to twelve months), and launched as a “Special Opportunities Fund.”
With Field, Jani Rautiainen (an experienced entrepreneur, investor, and CoFounder of Property Guru), and myself as Venture Partners, we launched the Vulpes Special Opportunities Fund.
We also decided to broaden the fund mandate from seed only to focusing on great founders with great (post-COVID-19) businesses in S.E. Asia from the Seed stage through to late Series A.
The fund capital was raised in an 8–12-week period.
Now it was time to start investing:
It is critical to invest in the right founders (this has always been our primary investment criteria, so no change required), but also to invest in the right industry sectors. This required new consideration, as different sectors would be impacted in different ways, to different extents, and over different timeframes.
We felt confident that the S.E. Asia and Pacific regions would weather COVID-19 better and recover significantly faster than many other geographic regions.
So, what have we learned so far?
We quickly saw an opportunity to reduce our buy-in valuations by encouraging Founders to source us some secondaries from existing early investors at a discount. Many existing investors welcomed the opportunity to sell some or all of their parcels due to either financial distress or just wanting to lock in some of their gains, given the level of financial uncertainty. We invested in the Founders current round but were sometimes able to reduce our buy-in valuation by doing a blend of the current round valuation and some discounted secondaries.
As we kicked off the investment process, we were aware that we would be taking a higher level of risk if we were not meeting the founding teams face to face (due to travel restrictions). Video calls were effective for pitches, but we needed local knowledge for effective due diligence. So, we leveraged our networks. There were founders we had previously invested in and trusted that were happy to get involved. In many cases, it has activated them to assist us in finding and qualifying investment opportunities in regions where we have no physical presence. We also activated our V.C./Investor partners and made a point to engage with the reputable early/existing investors that had been working with the prospective Founders. We were able to explore the Founders reporting frequency, quality, and how effectively they engaged with Advisors, mentors, and coaches etc.
We have found that many of our investee companies are recovering their revenue/growth positions to better than pre-COVID-19 levels as they have benefitted from establishing new revenue lines and have had to operate with dramatically reduced cost bases. Some have been able to increase their rate of growth with a fraction of their previous marketing spend. Time will tell whether this is sustainable in the long term, but for now, some are enjoying a period of enhanced performance.
The sectors we have invested in have been predominantly in sectors that have benefitted from the dramatic growth in demand driven by people working from home and increasing their time online, such as:
- Ecommerce, delivery and logistics and Influencers
- Esports, Online Investing, and Telehealth
- Food delivery and restaurant bookings
Or Enterprise SaaS products experiencing strong trends in digitization such as:
- Fintech, Insurtech, Property tech
- Food security and supply chain
- Customer Experience Solutions
- Like many businesses, during COVID-19, we have had to make changes to operate, and often it has improved our business for the long term. The Fund has made eleven investments in just over six months.
The Fund has the capital to make at least a further eight investments, and we are about to launch another (significantly larger) Fund also focused on S.E. Asia. The new Fund will have a similar mandate but a longer investment period and the ability to follow-on. We are buoyed by the fact that we have developed a reliable and robust network of Founders and V.C. partners throughout the Region and have developed improved systems and processes specific to investing in S.E. Asia.
We expect much higher levels of Venture Capital will flow in to S.E. Asia as other regions are economically challenged and slower to recover. Many may also decide they are overexposed to their own Region. This will see increased activity and some good opportunities for growth in S.E. Asia. Over time this will cause upward pressure on valuations.
Disclaimer
Disclaimers and Important Notes
This information (“Information”) is for private use, for information and discussion purposes only. The Information is not and does not constitute, and under no circumstances should it be considered as or intended to form part of any offer, recommendation, invitation or solicitation to subscribe to or to enter into any transaction, nor is it calculated to invite or permit the making of offers to the public to subscribe to or enter into any transaction and should not be viewed as such. The Information does not intend to express any opinion on the merits of buying, selling or holding a particular investment product or a class of investment products.
This is not investment research and it is for information only. It should not be relied upon as financial advice. It has not been prepared in accordance with legal requirements designed to promote the independence of research, it is not intended to constitute independent, impartial or objective research analysis or recommendations and should not be treated or relied on as such. The provision of this Information is not regulated by any regulatory authority, including the Monetary Authority of Singapore, or under any regulation, including the Financial Advisors Act of Singapore and the Securities and Futures of Singapore. Notwithstanding this, the Information is not presented with the intention of inducing a person to buy, sell or hold a particular investment product or a class of investment products. Any terms, conditions and opinions contained herein may have been obtained from various sources and neither “Vulpes” nor any of its related companies or affiliates nor any of their respective directors or employees make any warranty, expressed or implied, as to its accuracy or completeness and thus assume no responsibility for it.
The Information may be subject to further revision, verification and updating and Vulpes undertakes no responsibility thereof. All figures and amounts stated are for illustration purposes only and shall not bind Vulpes. Vulpes does not act as an adviser and is not in the business of providing financial advice. Vulpes assumes no fiduciary responsibility or liability for any consequences, financial or otherwise, arising from any arrangement or entrance into any transaction in reliance on the information contained herein. This Information is generic and is not intended to provide personal investment advice and does not take into account the specific investment objectives, the financial situation and the particular needs of persons who may receive or read this Information. Investors should therefore seek financial, legal and other advice regarding the appropriateness of investing in any securities or the investment strategies discussed in the Information. The Information may contain forward looking statements which are often but not always identified by the use of words such as “anticipate”, “believe”, “estimate”, “intend”, “plan”, “expect”, “forecast”, “predict” and “project” and statements that an event or result “may”, “will”, “can”, “should”, “could” or “might” occur or be achieved and other similar expressions. Such forward looking statements are based on assumptions made and information currently available to us and are subject to certain risks and uncertainties that could cause the actual results to differ materially from those expressed in any forward-looking statements. Readers are cautioned not to place undue relevance on these forward-looking statements. Vulpes expressly disclaims any obligation to update or revise any such forward looking statements to reflect new information, events or circumstances after the date of this publication or to reflect the occurrence of unanticipated events.
All information, estimates, forecasts and opinions included in this document may be subject to change without notice. Changes in market conditions or in any assumptions may have a material impact on any estimates or opinion stated. In any event, past performance is no guarantee of future results, and future results may not meet expectations due to a variety of economic, market and other factors. Any information relating to past performance, or any future forecast based on past performance or other assumptions, is not necessarily a reliable indicator of future results. If the Information has been distributed by electronic transmission, such as e-mail, then such transmission cannot be guaranteed to be secure or error-free as information could be intercepted, corrupted, lost, destroyed, arrive late or incomplete, or contain viruses. The sender therefore does not accept liability for any errors or omissions in the contents of the Information, which may arise as a result of electronic transmission. The Information is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Without prejudice to the foregoing, the reader is to note that additional disclaimers, warnings or qualifications may apply based on geographical location of the person or entity receiving this report.
Country Specific Notices
United Kingdom: This document does not constitute an offer or invitation to purchase or subscribe for any securities, and neither this document nor anything contained herein shall form the basis of or be relied upon in connection with or act as an inducement to enter into any contract or commitment whatsoever.
This document is only addressed to and directed at persons resident in the United Kingdom and who are “Qualified Investors” within the meaning of article 2(e) of The Prospectus Regulation (EU) 2017/1129 (as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018) (“Qualified Investors”). In addition, in the United Kingdom, this document has not been approved by an authorised person pursuant to section 21 of the Financial Services and Markets Act 2000 (“FSMA”) and, as such, this document is being distributed only to, and is directed only at, qualified investors (i) who have professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) order 2005 (the “Order”) or are Qualified Investors falling within article 49 of the Order, and (ii) to whom the information may otherwise lawfully be communicated (all such persons together being referred to as “Relevant Persons”). The information in this document must not be acted on or relied on in the United Kingdom, by persons who are not relevant persons. This document must not be acted on or relied on in the United Kingdom, by persons who are not both Relevant Persons and Qualified Investors.
United States of America: This document is not intended as an offer or solicitation for the purchase or sale of any securities, financial instrument or product or to provide financial services. It is not intended to create legal relations on the basis of information provided herein.
Singapore: If this document is distributed in Singapore, it is made available through general information circulation only it is not intended as an offer or solicitation for the purchase or sale of any securities, financial instrument or product or to provide financial services. It is not intended to create legal relations on the basis of information provided herein. The contents of the Materials have not been reviewed by in the Monetary Authority of Singapore.
South Africa: This publication is not, nor is it intended to be, advice as defined and/or contemplated in the (South African) Financial Advisory and Intermediary Services Act, 37 of 2002, or any other financial, investment, trading, tax, legal, accounting, retirement, actuarial or other professional advice or service whatsoever. The views in this publication are those of the author(s) and are subject to change and “Vulpes” has no obligation to update its opinions or the information in this publication. If this publication contains recommendations, those recommendations reflect solely and exclusively those of the author(s) and such opinions were prepared independently of any other interests. This publication does not constitute personal investment advice.
Read more insights

SCANCELL HOLDINGS PLC: Scope 2 melanoma trial beats milestones
Life Sciences
Scancell’s Phase 2 SCOPE trial for advanced melanoma impressed – with Initial data from 11…
Author: Jamshed Dadabhoy
Date: September 23, 2023